La cadena de opciones muestra datos clave de las opciones de acciones de Camp4 Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Camp4 Therapeutics..

Camp4 Therapeutics (NASDAQ:CAMP) Bolsa, Cadena de Opciones

CAMP4 THERAPEUTICS CORP

Camp4 Therapeutics

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

CalAmp

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics Corp

CalAmp Corp

Camping World Holdings, Inc. Class A Common Stock

Camping World Holdings Inc

Campbell International Holding Corp

CAMPBELL RES INC by Campbell Resources Inc.

Campbell Resources Inc

News

Press Releases

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Management

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Earnings

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

Health Care

General

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

Sequans Appoints Jason W. Cohenour to Board of Directors

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMP

LTRX

RFIL

SQNS

SWIR

TSX:BLN

TSX:SW

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

BeyondSpring

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

CervoMed

Cue Biopharma

CEL-SCI

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Evaxion

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

MiNK Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lite Strategy

MediciNova

OS Therapies

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Plus Therapeutics

Senti Biosciences

X4 Pharmaceuticals

Cantor Fitzgerald

Piper Sandler

Wedbush

Leerink Partners

JP Morgan

Comments

Camp4 Therapeutics

Camp4 Therapeutics (CAMP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL